Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Citigroup
C
|
+$28M |
| 2 |
Coursera
COUR
|
+$20.3M |
| 3 |
PINC
Premier
PINC
|
+$18.6M |
| 4 |
Lyft
LYFT
|
+$18.3M |
| 5 |
PayPal
PYPL
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$39M |
| 2 |
Dropbox
DBX
|
+$30.5M |
| 3 |
Vontier
VNT
|
+$24.8M |
| 4 |
FISV
Fiserv Inc
FISV
|
+$16.2M |
| 5 |
F5
FFIV
|
+$15.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.57% |
| 2 | Communication Services | 12.72% |
| 3 | Healthcare | 12.33% |
| 4 | Consumer Discretionary | 10.59% |
| 5 | Industrials | 6.66% |
Similar funds
Invenomic Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Invenomic Capital Management held 162 positions worth $1.97B, up 11% from $1.77B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Invenomic Capital Management deployed $159M of net new capital in Q2 2023, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was Citigroup: 596,817 shares worth $27.5M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 30% a quarter earlier, followed by Communication Services and Healthcare.
On the sell side, the largest reduction was Dropbox, an estimated $30.5M trimmed.
- Invenomic Capital Management's largest Q2 2023 buy was Citigroup: 596,817 shares worth $27.5M.
- Invenomic Capital Management added most to Coursera in Q2 2023, an estimated $20.3M increase.
- Invenomic Capital Management's biggest Q2 2023 reduction was Dropbox, cutting an estimated $30.5M.
- Invenomic Capital Management fully exited Meta Platforms (Facebook) in Q2 2023, selling an estimated $39M.
- Invenomic Capital Management's ten largest holdings make up 32% of its $1.97B portfolio in Q2 2023.
- Invenomic Capital Management opened 22 new positions and closed 28 in Q2 2023.
- Invenomic Capital Management's portfolio value rose 11% quarter-over-quarter to $1.97B.
Based on Invenomic Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.